BiVictriX Therapeutics Huge Announcement
BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) said it has selected a drug candidate from its BVX001 programme for clinical trials.
This decision stems from strong preclinical trial data that showed the drug demonstrated a significant tumour 'regression' of up to 93% in a mouse model of acute myeloid leukaemia (AML), with no reported side effects.
In a four-week study, the efficacy of two variations of BVX001 was compared to both an untreated group and a high dose of Cytarabine, a chemotherapy used to treat AML.
The study included three different dosage schedules for BVX001. According to the data, all BVX001 treatment plans showed a marked reduction in tumour growth compared to the untreated group.
Remarkably, at a dosage of 10mg/kg twice a week, the tumour regression rate stood at 93% and 89% respectively for the two BVX001 variations.
In a statement, Tiffany Thorn, CEO of BiVictriX, said: "This strong in vivo efficacy data we are seeing from our first clinical candidate provides clear validation for our first-in-class Bi-Cygni therapeutics and their potential to provide much-needed further treatment options for patients with acute myeloid leukaemia, one of the most aggressive forms of cancer."
She added that researchers will continue to progress BVX001 through further preclinical studies that help it gain regulatory approval to begin human trials.
It is also "seeking suitable third-party partnerships to support manufacturing and clinical development activities as well as commercialisation of the asset", Thorn told investors.
The company's Bi-Cygni technology has been developed to create targeted cancer drugs with fewer toxicity issues.
Often the treatment of tumours and blood-borne diseases is a high-wire act for a physician, who has to administer the optimal dose to kill off the disease while ensuring the already sick patient doesn't feel the full force of the toxic side effects.
Drugs that take out the cancer cell, leaving healthy cells intact, would largely resolve this issue.
However, this precision approach comes with a massive challenge – and one that has largely stumped scientists for the last three decades.
BiVictriX using its Bi-Cygni platform is aiming to crack this conundrum.
